Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
Recent Posts
- New NJACTS Publication
- Researchers Track Sharp Increase in Diagnoses for Sedative, Hypnotic and Anxiety Use Disorder in Young Adults.
- Join NJ ACTS Genetically informed Research, Education, And Treatment (GREAT) Core TODAY at 10:30 am
- A Common Antihistamine Shows Promise in Treating Liver Complications of a Rare Disease.
- NJ ACTS Biostatistics, Epidemiology, Research Design (BERD) Workshop Series on 2/20
Categories
- Community (2,134)
- Covid (981)
- CTO Events (6)
- News (2,724)
- Pilots (21)